Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth
- 3 May 2010
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 107 (20), 9446-9451
- https://doi.org/10.1073/pnas.0911863107
Abstract
Despite abundant evidence that aberrant Rho-family GTPase activation contributes to most steps of cancer initiation and progression, there is a dearth of inhibitors of their effectors (e.g., p21-activated kinases). Through high-throughput screening and structure-based design, we identify PF-3758309, a potent (K(d) = 2.7 nM), ATP-competitive, pyrrolopyrazole inhibitor of PAK4. In cells, PF-3758309 inhibits phosphorylation of the PAK4 substrate GEF-H1 (IC(50) = 1.3 nM) and anchorage-independent growth of a panel of tumor cell lines (IC(50) = 4.7 +/- 3 nM). The molecular underpinnings of PF-3758309 biological effects were characterized using an integration of traditional and emerging technologies. Crystallographic characterization of the PF-3758309/PAK4 complex defined determinants of potency and kinase selectivity. Global high-content cellular analysis confirms that PF-3758309 modulates known PAK4-dependent signaling nodes and identifies unexpected links to additional pathways (e.g., p53). In tumor models, PF-3758309 inhibits PAK4-dependent pathways in proteomic studies and regulates functional activities related to cell proliferation and survival. PF-3758309 blocks the growth of multiple human tumor xenografts, with a plasma EC(50) value of 0.4 nM in the most sensitive model. This study defines PAK4-related pathways, provides additional support for PAK4 as a therapeutic target with a unique combination of functions (apoptotic, cytoskeletal, cell-cycle), and identifies a potent, orally available small-molecule PAK inhibitor with significant promise for the treatment of human cancers.Keywords
This publication has 45 references indexed in Scilit:
- PAK signaling in oncogenesisOncogene, 2009
- Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer TherapyAnnual Review of Pharmacology and Toxicology, 2009
- Pak protein kinases and their role in cancerCancer and Metastasis Reviews, 2009
- Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancerProceedings of the National Academy of Sciences of the United States of America, 2008
- The Pak4 Protein Kinase Plays a Key Role in Cell Survival and Tumorigenesis in Athymic MiceMolecular Cancer Research, 2008
- Rho GTPases in cancer cell biologyFEBS Letters, 2008
- Recognizing and exploiting differences between RNAi and small-molecule inhibitorsNature Chemical Biology, 2007
- Rho GTPases: functions and association with cancerClinical & Experimental Metastasis, 2007
- ARF1-mediated actin polymerization produces movement of artificial vesiclesProceedings of the National Academy of Sciences of the United States of America, 2007
- Crystal Structures of the p21-Activated Kinases PAK4, PAK5, and PAK6 Reveal Catalytic Domain Plasticity of Active Group II PAKsStructure, 2007